國立虎尾科技大學 |

Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways/ edited by Yosef Yarden, Moshe Elkabets.
其他作者:	Yarden, Yosef.
面頁冊數:	XX, 242 p. 22 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer research. -
電子資源:	https://doi.org/10.1007/978-3-319-67932-7
ISBN:	9783319679327

Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways[electronic resource] /edited by Yosef Yarden, Moshe Elkabets. - 1st ed. 2018. - XX, 242 p. 22 illus. in color.online resource. - Resistance to Targeted Anti-Cancer Therapeutics,152196-5501 ;. - Resistance to Targeted Anti-Cancer Therapeutics,4.

Resistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis.

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

ISBN: 9783319679327

Standard No.: 10.1007/978-3-319-67932-7doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
LDR:02602nam a22004095i 4500 001 992576
003 DE-He213
005 20200630123511.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319679327 $9 978-3-319-67932-7
024 7 $a 10.1007/978-3-319-67932-7 $2 doi
035 $a 978-3-319-67932-7
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways $h [electronic resource] / $c edited by Yosef Yarden, Moshe Elkabets.
250 $a 1st ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a XX, 242 p. 22 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 15
505 0 $a Resistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis.
520 $a This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
650 0 $a Cancer research. $3 1253664
650 1 4 $a Cancer Research. $3 668358
700 1 $a Yarden, Yosef. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1063738
700 1 $a Elkabets, Moshe. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1201667
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319679303
776 0 8 $i Printed edition: $z 9783319679310
776 0 8 $i Printed edition: $z 9783030098179
830 0 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 4 $3 1254768
856 4 0 $u https://doi.org/10.1007/978-3-319-67932-7
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)